MedTrace Logo

Triple Negative Breast Cancer Trial

NCT00532727 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2019-02-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether there is greater activity for carboplatin than a taxane standard of care (docetaxel) in women with ER-, PR- and HER2- breast cancer. The trial aims to recruit between 370 and 450 patients.

Conditions

Interventions

DRUG

Carboplatin

AUC 6 every 3 weeks for six cycles (18 weeks)

DRUG

Docetaxel

100mg/m2 every 3 weeks for six cycles (18 weeks)

Sponsors & Collaborators

Principal Investigators

  • Andrew Tutt, MB ChB, MRCP, FRCR, PhD · King's College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2016-03-31
Completion
2020-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00532727 on ClinicalTrials.gov